Schizophrenia

Suboptimal Neuromotor Development May Increase Genetic Risk for Schizophrenia

Suboptimal Neuromotor Development May Increase Genetic Risk for Schizophrenia

By

Nonoptimal infant neuromotor development was linked to genetic risk for schizophrenia, but not bipolar disorder.

Interleukin-6 Blockade, Low C-reactive Protein Levels May Increase Schizophrenia Risk

Interleukin-6 Blockade, Low C-reactive Protein Levels May Increase Schizophrenia Risk

Specific inflammatory biomarkers may have an impact on the risk of developing schizophrenia.

Social Stigma May Negatively Impact Treatment Adherence in Schizophrenia

Social Stigma May Negatively Impact Treatment Adherence in Schizophrenia

By

Poor adherence to antipsychotic treatment in schizophrenia may be attributable to socially negative representations of schizophrenia.

Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition

Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition

By

Patients with schizophrenia, schizoaffective disorder, and psychotic bipolar disorder were examined for anticholinergic burden.

Depression, Schizophrenia Identified With Objective Blood Biomarker

Depression, Schizophrenia Identified With Objective Blood Biomarker

NMDA receptor signaling is increased in patients with depression and reduced in those with schizophrenia.

Antipsychotic Polypharmacy Prevalent Despite Guidelines

Antipsychotic Polypharmacy Prevalent Despite Guidelines

Having schizophrenia and a length of stay of 90 days or more were the strongest predictors of polypharmacy.

Antipsychotics May Elevate Risk of Movement Disorders

Antipsychotics May Elevate Risk of Movement Disorders

By

The odd relationship may have more to do with the mental disorder than the drugs.

Excessive Activity in Genetic Variant May Underly Schizophrenia

Excessive Activity in Genetic Variant May Underly Schizophrenia

By

Researchers uncovered a link between elevated levels of C4A protein, excessive synaptic pruning, and the development of schizophrenia.

Inhibitory Neuron Deficit May Contribute to Social Withdrawal in Schizophrenia

Inhibitory Neuron Deficit May Contribute to Social Withdrawal in Schizophrenia

By

A mouse model of schizophrenia showed a significant decrease in inhibitory CA2 neurons.

Biotypes Highlight Unique Biological Manifestations of Psychosis

Biotypes Highlight Unique Biological Manifestations of Psychosis

By

The unique biotypes may allow for more targeted treatments to be developed.

Clozapine Beneficial for Treatment-Resistant Schizophrenia

Clozapine Beneficial for Treatment-Resistant Schizophrenia

Patients taking clozapine were less likely to need additional antipsychotic medications.

Differences in Paracingulate Sulcus Linked to Hallucinations in Schizophrenia

Differences in Paracingulate Sulcus Linked to Hallucinations in Schizophrenia

By

A 1 cm deficit in PCS length contributed to a 20% increased risk for hallucinations.

FDA Approves Injectable for Schizophrenia

FDA Approves Injectable for Schizophrenia

The most common side effect reported was akathisia.

fMRI May Help Identify Correct Schizophrenia Treatment

fMRI May Help Identify Correct Schizophrenia Treatment

The personalized approach to treatment could help prevent trial-and-error periods.

FDA Approves Vraylar for Bipolar Disorder, Schizophrenia

FDA Approves Vraylar for Bipolar Disorder, Schizophrenia

The FDA's approval was based on data from controlled trials in adults with manic or mixed episodes of bipolar I disorder and schizophrenia.

Antipsychotics May Contribute to Gray Matter Loss in Schizophrenia

Antipsychotics May Contribute to Gray Matter Loss in Schizophrenia

By

Second-generation antipsychotics appear to have a neuroprotective effect on the brain.

Speech Analysis Tool May Help Identify Psychosis

Speech Analysis Tool May Help Identify Psychosis

Automated speech analysis more accurately classified at-risk young people than clinical ratings.

Omega-3 Supplement May Help Stave Off Schizophrenia

Omega-3 Supplement May Help Stave Off Schizophrenia

A three-month course of daily omega-3 supplements prevented the progression to a psychotic disorder in the majority of participants.

iPad App May Improve Memory in Schizophrenia Patients

iPad App May Improve Memory in Schizophrenia Patients

The game is designed to improve episodic memory.

Schizophrenia Patients Have Abnormal Brain Structure

Schizophrenia Patients Have Abnormal Brain Structure

Identifying the abnormalities may help in the development of news treatments.

Encenicline Gets Fast Tracked for Cognitive Impairment in Schizophrenia

Encenicline Gets Fast Tracked for Cognitive Impairment in Schizophrenia

The FDA has granted Fast Track designation to encenicline for the treatment of cognitive impairment in schizophrenia.

Exercise for Improved Neurocognition in Schizophrenia

Exercise for Improved Neurocognition in Schizophrenia

Aerobic activity seems to be beneficial, but the results of the study need to be duplicated.

Sign Up for Free e-newsletters

CME Focus